Press release | Lund 2026-11-20

Coegin Pharma's Nomination Committee appointed for the 2027 Annual General Meeting

The Nomination Committee of Coegin Pharma AB ("Coegin") has been appointed in accordance with the guidelines adopted at the Annual General Meeting on May 21, 2026.

The following individuals have been appointed as members of the Nomination Committee for the 2027 Annual General Meeting:

Ulrika Arver, representing Alveco Invest AB.

Anna Svenstig, representing Bengt Svenstig.

Lennart Börjesson, representing his own shareholdings.

Eva Sjökvist Saers, in her capacity as Chair of the Board of Directors of Coegin.

The Nomination Committee is tasked with performing the duties assigned to it under the Swedish Corporate Governance Code. The Committee is responsible for preparing proposals for the 2027 Annual General Meeting regarding the Chair of the Meeting, members of the Board of Directors, the Chair of the Board, the auditor, board and auditor remuneration, as well as any potential changes to the guidelines for the Nomination Committee.

The Annual General Meeting will be held on May 26, 2027, in Lund, Sweden. Shareholders who wish to submit proposals to the Nomination Committee are welcome to do so no later than January 20, 2027. Proposals should be sent via email to info@coeginpharma.com.

The Nomination Committee's proposals will be presented in the notice convening the Annual General Meeting and on the company's website, www.coeginpharma.com.

For further information, please contact:

Jens Eriksson, CEO, or Lars B. Rasmussen, CFO
Email: info@coeginpharma.com
Phone: +46 72 221 24 21

About Coegin Pharma

Coegin Pharma is a Swedish innovation company developing and commercializing advanced cosmetic technologies for hair and skin. Its flagship innovation, Follicopeptide®, is a patented, clinically developed peptide technology targeting hair thinning, commercialized through selected partners and the Company's VEXIENNE® brand. Coegin is also developing NPP-4, a next-generation cosmetic peptide innovation for skin tone enhancement.

Coegin Pharma AB
c/o Medicon Village
223 81 Lund, Sweden
Registration number
559078-0465
coeginpharma.com
info@coeginpharma.com

With proprietary peptide technology, scalable in-house production and flexible commercial models, Coegin is building a differentiated platform for science-based cosmetic products.

Coegin Pharma's share is listed on NGM Growth Market and dual-listed on Börse Stuttgart. The Company is headquartered in Lund, Sweden.

For more information, including company updates and social media links, visit coeginpharma.com

Coegin Pharma AB
c/o Medicon Village
223 81 Lund, Sweden
Registration number
559078-0465
coeginpharma.com
info@coeginpharma.com